1Souquet PJ, Chauvin F, Boissel JP, et al. Polchemotherapy in advanced non small cell lung cancer: a meta-analysis [J]. Lancet, 1993, 342 (8826) :19-21.
2Therasse P,Arbuck SG,Eisenhauer EA,et al.New guidelines to evaluate the response to treatment in solid tumors[J].J Natl Cancer Inst,2000,92(3):205～216.
3Watanabe H,Yamamoto S,Kunitoh H,et al.Tumor response to chemotherapy:The validity and reproducibility of RECIST guidelines in NSCLC patients[J].Cancer Sci,2003,94(11):1015～1020.
4Gehan EA,Tefft MC.Will There Be Resistance to the RECIST(Response Evaluation Criteria in Solid Tumors)[J]?J Natl Cancer Inst,2000,92(3):179 ～181.
5Lavin PT,Flowerdew G.Studies in variation associated with the measurement of solid tumors[J].Cancer,1980,46(5):1286 ～ 1290.
6James K,Eisenhauer E,Christian M,et al.Measuring response in solid tumors:unidimensional versus bidimensional measurement[J].J Natl Cancer Inst,1999,91(6):523～528.
7Mazumdar M,Smith A,Lawrence H,et al.A statistical simulation study finds discordance between WHO criteria and RECIST guideline[J].J Clin Epidem,57(4):358～365.
8万德森主编.临床肿瘤学[M].第3版.北京:北京科学出版社,2002.156.
9Miller AB,Hoogstraten B,Staquet M,et al. Reporting results of cancer treatment [J]. Cancer, 1981,47(1) : 207-214.
10Kaye SB. Gemcitabine :Current status of phase Ⅰ and Ⅱ trials [J]. Clin Oncol,1994,12(8):1527-1531.
6Socinski MA, Crowell R, Hensing TE, et al. Treatment of non-small cell lung cancer, stage IV: ACCP evidence- based clinical practice guidelines (2nd edition ) [ J ]. Chest,2007,132 (2) :77S - 89S.
7Huang Y, Chen Z, Zhou C, et al. The modulation of thymosin alphalin the maturation, differentiation and function of murin bone marrow - derived dendritic-cells in the absence or presence of tumor necrosis factor-alpha [ J ]. Int Immunopharmacol,2004 ,4 (4) :539 - 546.
8Ohmori H, Kamo M, Yamakoshi K, et al. Restoration of immunocyte functions by thymosin alphal in cyclophosphamide-induced immunodeficient mice [ J ]. Immunopharmacol Immunotoxicol,2001, 23 ( 1 ) :75 - 82.
9Garaci E,Pica F, Rasi G,et al. Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application[ J ]. Int Immunopharmacol, 2000,22 ( 12 ) : 1067 - 1076.
10Hadden JW. Immunodeficiency and cancer:prospects for correction. [ J]. Int Immunopharmacol, 2003,3 ( 8 ) : 1061 - 1071.
